







Osteoarthritis Tool

The Osteoarthritis (OA) Tool has been developed for primary care providers who are managing patients with new or recurrent joint pain consistent with OA in the hip, knee or hand. This tool will help clinicians identify symptoms and provide evidence-based, goal-oriented non-pharmacological and pharmacological management while identifying triggers for investigations or referrals.

Section 1: History



Section 2: Physical Examination




Meniscus Testing: Use the Thessaly Test⁹



- \bullet Screen for discrete meniscal pathology, may change management
- A positive test is indicated by reports of pain on the joint line or by joint locking or catching
- If positive do a full meniscal testing and imaging
- The Thessaly test has higher sensitivity and specificity compared to the sensitivity and specificity of the Apley's test when assessing for meniscal tears

B. HAND EXAMINATION

Observati	ons				
Assess for bilateral deformities and atrophy.				`	
Multiple joint involvement will affect grip strength, and first finger and thumb involvement will affect pinch.					
	Thumb	Index Finger (1st)	Middle Finger (2nd)	Ring Finger (4th)	Little Finger (5th)
Swelling		□ MCP	□ MCP	□ MCP	□ MCP
and/or Tenderness	□ MCP	🗆 PIP	🗆 PIP	🗆 PIP	🗆 PIP
Tendemess	🗆 PIP	🗆 DIP	🗆 DIP	🗆 DIP	🗆 DIP
Deformity		□ MCP	□ MCP	□ MCP	□ MCP
	□ MCP	🗆 PIP	🗆 PIP	🗆 PIP	🗆 PIP
	🗆 PIP	🗆 DIP	🗆 DIP	🗆 DIP	🗆 DIP



Rule Out De Quervain's Tenosynovitis If Some Pain Is Present¹¹



Positive: Pain with ulnar deviation of the wrist If positive, treat specifically and consider association with inflammatory arthritis.


Negative: No pain with ulnar deviation If negative, proceed with osteoarthritis management.

Functi	Function & Strength: Grip & Pinch ¹⁰				
	Grip	Pinch			
Score	Muscle Response	Score Grip	Score Pinch	Osteoarthritis Stage	
5	Maximum muscle contraction Grip: Examiner cannot pull thumb away from patient grip Pinch: Examiner unable to separate thumb pinch position			Normal to early	
4	Good muscle contraction Grip: Examiner can partially slide thumb from patient grip Pinch: Examiner can partially separate thumb pinch position			Early to moderate	
3	Moderate muscle contraction Grip: Examiner can slide thumb from patient squeeze Pinch: Examiner can separate thumb pinch positions			Moderate	
2	Weak muscle contraction Grip: Patient unable to fully squeeze examiner's thumb Pinch: Patient unable to hold a circular position between thumb and finger			Advanced	
1	Flicker of activity			Not consistent with osteoarthritis	
0	No muscle contraction			Not consistent with osteoarthritis	

Section 3: Diagnosis

It is helpful to diagnosis osteoarthritis by the joint affected and clinical stage. Patients have reported that they find it helpful to know what joint(s) are affected and clinical stage(s). 'Staging' is based on the clinical assessment of function, mobility and joint examination. Determining clinical stage may guide management principles and assist patients to understand the clinical severity of their osteoarthritis.

Clinical Assessment of Osteoarthritis Stage					
Нір	Knee	Hand			
🗆 Early	🗆 Early	🗆 Early			
□ Moderate	□ Moderate	□ Moderate			
□ Advance	□ Advance	□ Advance			



Kellgren and Lawrence Radiographic Criteria for Assessment of OA*22					
Correlation between clinical diagnosis and radiological staging may be useful when patients are not responding to treatment or potential surgical planning is required.			Mild/Early – Normal Joint space with definite osteophyte formation Moderate/Mid – Moderate joint space reduction/moderate multiple osteophytes Advanced/Severe – Joint space greatly reduced, subchondral sclerosis, large osteophytes, deformity of bone ends.		
		~	~		1
Radiographic grade	0	I	Ш	111	IV
Classification	Normal	Doubtful	Mild	Moderate	Severe
Description	No features of OA	Minute osteophyte; doubtful significance	Definite osteophyte: normal joint space	Moderate joint-space reduction	Joint space greatly reduced; subchondral sclerosis

*Radiography does not reliably correlate with symptoms

Referral			
Outpatient Rehabilitation Provider	 Any one of the following: Absence of red flags Patient whose medical pain management has been optimized to be able to engage in active exercises Patient who is open to implementing new information and/or strategies into their management program (e.g., goal setting, self-management focus) 		
Sport & Exercise Medicine Physician	 Patients who require a complete assessment to evaluate musculoskeletal pathology Patients who need an assessment of exercise capacity and recommendations Patients who require an integrated rehabilitation strategy including pain management 		
Pain Specialist	 High constant pain levels that interfere with activities and function Presence of Yellow Flags Patient who identifies active goals for treatment and self-management Patient who is open to implementing new information into their management program Patient who is on escalating / high doses of pain medications (e.g., opioids) 		
Rheumatologist	 Patients at risk for inflammatory arthritis Small and large joint polyarthritis symptoms Systemic symptoms (weight loss, fatigue) Non-articular features such as rash, inflammatory bowel disease, or psoriasis 		
Orthopaedic Surgeon	 Patients with escalating pain medication and/or reduced effectiveness of pain management Patient with significant reduction of joint mobility impacting activities of daily living and quality of life. Failure of a 12-week compliant evidence-based treatment program 		

	Hip & Knee	Hand	
ł	RECOMMENDED	RECOMMENDED	
	Weight Management	Assistive Devices	
	• The relative risk is increased for BMI classified as overweight (1.8), obese (2.4) and very obese (3.2) as compared to normal weight ¹²	• Hand or thumb splints can improve hand function and decrease pain, consider referral to therapies	
	• Achieving a weight loss of 5% of total body weight for effective treatment	Neuromuscular Training	
	Refer to dietician if needed ¹²	Aim for 8 repetitions of exercise, increase to 15-20	
	Physical Activity	repetitions, 1-2 times per day	
	 Recommend regular physical activity: promote activity as tolerated and if 	 Take a day off after strengthening 	
	able, target 150 minutes total per week; aim for 30 minutes 5 days a week. ¹³	Examples of hand Neuromuscular Training	
	 Encourage maintenance of strength and cardiovascular fitness through exercise and daily activity with appropriate pain management.¹³ 	 Make a fist, spread fingers, opposing thumb to each fingertip 	
	 Choose activities that are easier for patient's joint(s) and patient preference, for example: 	Joint Protection ²⁴	
	Cardiovascular and/or resistance land based exercise (e.g., walking,	 Reduce risk of trauma with patient education 	
	 biking) Neuromuscular control (e.g., Yoga, Tai Chi) 	 Reduce the effort needed to do a task – use labour savin gadgets or equipment, avoid lifting heavy objects, 	
	 For advanced OA consider aquatic exercises like swimming, aqua fit or 	reduce the weight on the affected joint	
	walking in a pool	 Pace yourself, rest for 30-60 seconds every 5-10 minute when stretching or moving joints 	
	 Consider fitness planning and exercise prescription by a qualified rehabilitation therapist. 	 Understand when the pain is worse during daily activities and suggest an action plan to minimize pain and increase 	
l	Assistive Devices	daily activities	
l	 Walking aids as needed (e.g., cane, walker or walking poles) 	• Distribute the weight over several joints for example	
	 A cane can help reduce the weight load in persons but needs to be properly fitted and used on the side contralateral to the affected joint 	spread the load between 2 hands • Avoid putting strain on the thumb(s), repetitive thumb	
l	 Shock absorbing shoes (e.g., gel or silicone insoles) 	movements, and/or prolonged grip in one position	
	• Knee underloader brace may be used in patients where one side of the joint	• Use a large grip as possible	
l	is less affected than the other side	Self-Management	
l	Joint Protection ²⁴	 Psychosocial interventions (e.g., cognitive behaviour therapy) may help with self-management of OA pain 	
l	Reduce risk of trauma with patient education	and function ¹⁴	
	 Reduce the effort needed to do a task – use labour saving gadgets or equipment, avoid lifting heavy objects, reduce the weight on the affected joint 	Refer to a mental health counselor if available	
	 Pace yourself, rest for 30-60 seconds every 5-10 minutes when stretching 	Thermal Therapy • Parrafin Wax ²⁵	
l	or moving joints	 Parrain wax²⁺ Heat pad: 10 minutes on, 10 minutes off or 15-20 minut 	
l	 Understand when the pain is worse during daily activities and suggest an 	on	
l	action plan to minimize pain and increase daily activities	 Avoid heat therapy when a malignancy or acute injury 	
	 Plan walks for places where there are benches to sit Keep joints in safe/neutral position for example; 	(e.g., open wounds, areas of recent bleeding, acute	
I	 Keep joints in safe/neutral position, for example: Avoid squatting, kneeling, twisting, low seats 	dermatitis, psoriasis, infection) is present	
	 Use raised toilet seats and raised bed 		
	 Reduce stress on joints while sleeping (e.g., firm mattress and pillow between the legs) 		
	Self-Management		
	 Psychosocial interventions (e.g., cognitive behavioural therapy) may help with self-management of OA pain and function ¹⁴ 		
	Refer to Mental Health Counselor if available		
	Thermal Therapy		
	• Heat pad: 10 minutes on, 10 minutes off or 15-20 minutes on		
	 Avoid heat therapy when a malignancy or acute injury (e.g., open wounds, areas of recent bleeding, acute dermatitis, psoriasis, infection) is present 		

Hip & Knee Hand RECOMMENDED RECOMMENDED Topical RECOMMENDED Topical Recommended scillation • Dose: 50 drops per knee TID or 40 drops per knee qid Analgesics • Acetaminophen is recommended as 1st-line therapy for hip/knee A (statistical) • Acetaminophen provides minimal pain relief and improvement in function for hip/knee OA (statistically significant, but clinically unimportant) ^{12/34} Hand OA Capsaicin (0.025%, 0.075%). Apply tid unopened skin Oral NSAIDs • NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or SAS, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebroxascular bleeding disorders, or hyperkalemia) ¹⁴⁻¹⁵ Analgesics SNRI • Duloxetine is recommended for knee OA ¹¹⁴ • Acetaminophen is recommended for patients without contraindications (renal impairment, severe liver impairment), istory of asthma or allergic-type reaction after taking NSAIDs or NSA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebroxascular bleeding and other bleeding disorders, or hyperkalemia) ¹⁴⁻¹⁵ Analgesics • Duioxetine is recommended for kine OA ¹¹⁶ • Opicids • Acetaminophen is recommended for patients without contraindications (renal impairment, severe liver impairment, severe liver impairment, seve					
Topical Topical Topical NSAIDS • Knee OA Diclofenac sodium ^{18,15} • Jose: 50 drops per knee TID or 40 drops per knee qid Analgesics • Acetaminophen is recommended as 1st-line therapy for hip/knee OA ^{13,15,15,10} • Hand OA Diclofenac diethylamine (1,16%, 2, 32%) Dose: 2-4g applied tid-qid • Acetaminophen provides minimal pain relief and improvement in function for hip/knee OA (statistically significant, but clinically unimportant) ^{17,18} • Acetaminophen provides minimal pain relief and improvement fixing NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia) ^{14,15} • Acetaminophen is recommended for knee OA ¹⁸ SNRI • Duloxetine is recommended for knee OA ¹⁸ • NSAIDs and CX-2 inhibitors are recommended for knee OA ¹⁸ • Topical • NSAID* • NSAIDS and CX-2 inhibitors are recommended for knee vector and inflammatory disease, cerebrovascular bleeding disorders, or hyperkalemia) ^{14,15} • Caetaminophen is recommended for knee VA ¹⁸ • Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral appentadol, oral codeine, oral morphine, oral same and preferences ^{11,14} • Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral appentadol, oral codeine, oral morphine, oral	10				
 Knee OA Diclofenac sodium^{14,15} Dose: 50 drops per knee TID or 40 drops per knee qid Analgesics Analgesics Acetaminophen is recommended as 1st-line therapy for hip/knee	10				
 Knee OA Diclofenac sodium^{14,15} Dose: 50 drops per knee TID or 40 drops per knee qid Analgesics Analgesics Acetaminophen is recommended as 1st-line therapy for hip/knee	10				
 Counterimination of the provides minimal pain relief and improvement in function for hip/knee OA (statistically significant, but clinically unimportant)^{17,18} Coral NSAIDs NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or pepticul Lers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,13} SNRI Duloxetine is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short the methange of All is in were neiner (inforther index on QALI)^{15,16} Corticosteroids Intra-articular corticosteroid injections may provide short the methange of All is in were neiner (inforther index on QALI)^{15,16} Corticosteroid injections may provide short the methange of All is in the patients' values and preferences^{14,15} Non-tramadol opioids (oral oxycodone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short the methange of All is in the patients' values and preferences^{14,15}	·4g				
 Analgesics Analgesics Acetaminophen is recommended as 1st-line therapy for hip/knee Acetaminophen provides minimal pain relief and improvement in function for hip/knee OA (statistically significant, but clinically unimportant)^{17,38} Cral NSAIDs NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} Non-tramadol is recommended for knee OA¹⁸ Opioids Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal fentany), and oral hydromorphone, oral tapentadol, oral codeine, oral morphine, oral atpentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral atpentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral atpentadol, oral codeine, oral morphine, oral atpentadol in patinent, bistory of a tame oralen					
 Acetaminophen is recommended as 1st-line therapy for hip/knee OA^{H435037} Acetaminophen provides minimal pain relief and improvement in function for hip/knee OA (statistically significant, but clinically unimportant)^{17,38} Oral NSAIDs NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI Duloxetine is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphne, oral tapentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral aymorphone has a small effect on pain or physical function with more side effect s^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short 	or Apply				
 Coral NSAIDs NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI Duloxetine is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral tapentadol, oral					
 Significant, but clinically unimportant)^{17:18} Oral NSAIDs • NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI • Duloxetine is recommended for knee OA¹⁶ Opioids • Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} • Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral apentadol, oral codeine, oral morphine, oral apentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral apentadol, oral codeine, oral morphine, oral apentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral apentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral tapentadol, oral codeine, oral morphine, oral apentadol, oral codeine, oral morphine, oral tapentadol, ora					
 NSAIDs and COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI Duloxetine is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{15,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral aymoprhone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short tam poine polie fiest buschese OA 1415 	id-qid to				
 without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI Duloxetine is recommended for knee OA¹⁸ Opioids Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral oxymoprhone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short tarm noi roll of ferbin endinge OA 1415 Corticosteroids					
 taking NSAIDs or ASA, severe uncontrolled heart failure, active gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI Duloxetine is recommended for knee OA¹⁸ Opioids Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral oxymoprhone) have a small effect on pain or physical function with more side effects^{20,21} Otrainable Dimensional COX-2 inhibitors are recommended for patients without contraindications (renal impairment, severe liver impairment, history of asthma or allergic-type reaction after taking NSAIDs or ASA, severe uncontrolled heart failure, act gastric duodenal or peptic ulcers and inflammatory disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} Non-tramadol opioids (oral oxycodone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short tram provide short tram provide short tram pain for a provide short tram pain the patients of the					
 disease, cerebrovascular bleeding and other bleeding disorders, or hyperkalemia)^{14,15} SNRI Duloxetine is recommended for knee OA¹⁸ Opioids Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral oxymoprhone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short tame and preference of the patient of the p					
 SNRI Duloxetine is recommended for knee OA¹⁸ Opioids Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral oxymoprhone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short tarm gain roligiffaching on lange OA 1415 					
 SNRI Duloxetine is recommended for knee OA¹⁸ Opioids Tramadol is recommended for hip and knee OA if it is in keeping with the patients' values and preferences.^{13,14} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine, oral oxymoprhone, transdermal fentanyl, and oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short torm more side offer bin archices OA 1415 					
 oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short torm pain and inspiration with more side effect bio enclosed on the pain and preferences^{14,15} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine oxymorphone, transdermal fentanyl, and oral hydromorpho have a small effect on pain or physical function with more side 	LS				
 oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short torm pain and inspiration with more side effect bio enclosed on the pain and preferences^{14,15} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine oxymorphone, transdermal fentanyl, and oral hydromorpho have a small effect on pain or physical function with more side 					
 oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short torm pain and inspiration with more side effect bio enclosed on the pain and preferences^{14,15} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine oxymorphone, transdermal fentanyl, and oral hydromorpho have a small effect on pain or physical function with more side 					
 oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short torm pain and inspiration with more side effect bio enclosed on the pain and preferences^{14,15} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine oxymorphone, transdermal fentanyl, and oral hydromorpho have a small effect on pain or physical function with more side 					
 oral hydromorphone) have a small effect on pain or physical function with more side effects^{20,21} Corticosteroids Intra-articular corticosteroid injections may provide short torm pain and inspiration with more side effect bio enclosed on the pain and preferences^{14,15} Non-tramadol opioids (oral oxycodone, transdermal buprenorphine, oral tapentadol, oral codeine, oral morphine oxymorphone, transdermal fentanyl, and oral hydromorpho have a small effect on pain or physical function with more side 					
Corticosteroids • Intra-articular corticosteroid injections may provide short torm pair relief for bin or know (A 1415)	th the				
• Intra-articular corticosteroid injections may provide short torm pain relia for bin or know 0.0.1415 oxymorphone , transdermal fentanyl, and oral hydromorpho have a small effect on pain or physical function with more sid					
• Intra-articular corticosteroid injections may provide short have a small effect on pain or physical function with more sid					
NOT RECOMMENDED NOT RECOMMENDED					
Capsaicin is not recommended for hip or knee OA ^{14,15} OBlucosamine not appropriate for disease modification but for hand OA. ¹³	ided for				
symptom relief, the evidence is uncertain. • Glucosamine not appropriate for disease modification but fo	for				
Chondroitin not appropriate ¹⁵ Symptom relief the evidence is uncertain. ¹⁵					
• Neuropathic pain modulators not recommended ¹⁵ • Chondroitin not appropriate ¹⁵ • Neuropathic pain modulators not recommended ¹⁵					
INCONCLUSIVE INCONCLUSIVE					
 Hip OA – no recommendation regarding the use of topical NSAIDS^{13,14} There are no recommendations for the use of Intra-articular hyaluronates for hand OA due to inconsistent conclusions an 					
• There are no consensus recommendations for the use of the meta-analyses ^{14,15}	-				
 Intra-articular hyaluronates, Platlet Rich Plasma and Stem Cell Herbal remedies and supplements-inconclusive evidence for use of these in the management of OA among the meta-analyses^{14,15} 	or the				
• Herbal remedies and supplements-inconclusive evidence for the use of these in the management of OA					
Legend tid-qid - 3 to 4 times a day					

EVALUATING RESPONSE TO TREATMENT

Once appropriate management has been initiated, the patient should be re-assessed between 2-4 weeks initial to determine next steps to reach optimal function. The response to goal-oriented treatment can be used as a guide for further clinical decision-making.

Improvement	No Change	Worsening
 Reduce pain medications Reinforce appropriate activity/exercise Gradual progressive increase in exercise/ activity to achieve activity goals Engage in comprehensive self management strategies Advise to return for care if experiencing persistent swelling, pain or stiffness 	 Re-assess Red Flags and Yellow Flags Review exercise/activity to avoid overuse or excessive repetition and schedule frequent breaks and recovery positions Review medication dosing, duration and consider next line of drug choice Consider referral criteria for goal oriented out- patient rehabilitation provider Re-assess Yellow Flags and if positive, consider referral to Pain Specialist/Pain Clinic Follow up in 1-2 weeks to see if patient is achieving treatment response 	 Re-assess Red Flags and consider referral criteria to rheumatologist. Evaluate need for investigations Re-assess Yellow Flags and if positive, consider referral to Pain Specialist/Pain Clinic. Reassess orthopaedic referral criteria for possible surgical assessment Review all elements in "No Change" column and look for patient compliance or comprehension gaps Set treatment priority goals and focus on one goal at a time to modify activities and progress at a slower pace

References

- [1] Hawker et al, Understanding the pain experience in hip and knee osteoarthritis an OARSI/OMERACT initiative. Osteoarthritis and Cartilage 16, 415-422 <u>http://www.oarsijournal.com/article/S1063-4584(07)00403-7/fulltext</u>
- [2] BC Practice Support Program. March 2016. Ver 7.8 Available: http://www.gpscbc.ca/sites/default/files/OA%20RA%20Algorithm%20ver%207%206_0.pdf
- [3] Getting a Grip on arthritis. Best Practice Guidelines. The Arthritis Society. 2017
- [4] Adapted from Physicians of Ontario Collaborating for Knowledge Exchange and Transfer (Red and Yellow Flag Cards) Available https://www.iwh.on.ca/system/files/documents/ pocket_flag_cards_2008_sheet.pdf
- [5] New Zealand Guidelines Group. New Zealand acute low back pain guide: Incorporating the guide to assessing psychosocial yellow flags in acute low back pain [Internet]. 2004 Oct [cited 2015 Nov 25]. Available from: http://www.acc.co.nz/PRD_EXT_CSMP/groups/external_communications/documents/guide/prd_ctrb112930.pdf
- [6] Cook C, Hededus E. Orthopedic Physical Examination Tests: An Evidence-Based Approach. 2nd ed. Pearson 2015
- [7] Centers for Disease Control and Prevention, The 30-Second Chair Stand Test, https://www.cdc.gov/steadi/pdf/30_second_chair_stand_test-a.pdf
- [8] British Columbia Guidelines and Protocols Advisory Committee. Osteoarthritis in Peripheral Joints Diagnosis and Treatment. 2008 Sep 15 http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/oa.pdf
- [9] Blyth M, Anthony I, Francq B, et al. Diagnostic accuracy of the Thessaly test, standardised clinical history and other clinical examination tests (Apley's, McMurray's and joint line tenderness) for meniscal tears in comparison with magnetic resonance imaging diagnosis. Health Technology Assessment, No. 19.62. 2015. <u>https://www.ncbi.nlm.nih.gov/ books/NBK310281/</u>
- [10] Arthritis Research UK. Examination of the hand and wrist. <u>http://www.arthritisresearchuk.org/health-professionals-and-students/video-resources/rems/examination-of-the-hand-and-wrist.aspx</u>
- [11] American Academy of Orthopaedic Surgeons, De Quervain's Tendinosis-Ortholnfo. http://orthoinfo.aaos.org/topic.cfm?topic=a00007
- [12] Niu J, Zhang Y, Torner J, Nevitt M, Lewis C, Aliabadi P, et al. Is Obesity a Risk Factor for Progressive Radiographic Knee Osteoarthritis? Arthritis Rheum. 2009;61(3):329-35.
- [13] Dunlop D, Song J, Lee J, Gilbert A, Semanik P, Ehrlich-Jones L et al. Physical Activity Minimum Threshold Predicting Improved Function in Adults With Lower-Extremity Symptoms. Arthritis Care & Research. 2017;69(4):475-483.
- [14] Hochberg M, Altman R, April K, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hnad, Hip and Knee. Arthritis Care & Research. 2012;64(4):465-74
- [15] McAlindon T, Bannuru R, Sullivan M, Arden N, Berenbaum F, Bierma-Zeinstra S, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage. 2014;22:363-88.
- [16] Derry S, Conaghan P, Da Silva J, Wiffen P, Moore R. Topical NSAIDS for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016 Apr 22;4:CD007400
- [17] Machado G, Maher C, Ferreira P, Pinheiro M, Lin C, Day R, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomized placebo controlled trials. BMJ. 2015;350:h12251
- [18] Ennis Z, Dideriksen D, Vaegter H, Handberg G, Pottegard A. Acetaminophen for chronic pain: A systematic review on efficacy. 2016;118:184-9.
- [19] Canadian Pharmacists Association, SNRIs, e-therapeutics.ca, access February 2, 2017
- [20] Cepeda M, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol. 2007;34(3):543-55.
- [21] Cepeda M, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006;19(3):CD005522.
- [22] Cooper C et al. In. Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. Oxford, NY. Oxford University Press, 1998 237-249
- [23] Vancouver Coastal Health. Ostearthritis Service Integration System. Manage Your OA. Exercise. http://oasis.vch.ca/manage-your-oa/exercise/, accessed March 3, 2017.
- [24] Vancouver Coastal Health. Ostearthritis Service Integration System. Manage Your OA. Joint Protection. <u>http://oasis.vch.ca/manage-your-oa/joint-protection/</u>, accessed March 3, 2017.
- [25] Paraffix Wax for Osteoarthritis.: <u>http://www.webmd.com/osteoarthritis/tc/paraffin-wax-for-osteoarthritis-topic-overview#1</u>, accessed March 3, 2017.

This Tool was developed in collaboration with the Arthritis Alliance of Canada ("AAC"), the College of Family Physicians of Canada ("CFPC") and the Centre for Effective Practice ("CEP"). Clinical leadership for the development of the tool was provided by Dr. Julia Alleyne MD, CAC(SEM), FCFP, in collaboration with a Clinical Working Group of subject matter experts. The tool was reviewed by other relevant target end users and key stakeholders. This Tool was funded by the AAC and the CFPC.

This tool was developed for licensed health care professionals in Canada as a quide only and does not constitute medical or other professional advice. Health care professionals are required to exercise their own clinical judgment in using this tool. Neither the Arthritis Alliance of Canada, the Centre for Effective Practice, the College of Family Physicians of Canada, nor any of their respective agents, appointees, directors, officers, employees, contractors, members or volunteers: (i) are providing medical, diagnostic or treatment services through this tool; (ii) to the extent permitted by applicable law, accept any responsibility for the use or misuse of this tool by any individual including, but not limited to, primary care providers or entity, including for any loss, damage or injury (including death) arising from or in connection with the use of this tool, in whole or in part; or (iii) give or make any representation, warranty or endorsement of any external sources referenced in this Tool (whether specifically named or not) that are owned or operated by third parties, including any information or advice contained therein.



Osteoarthritis Tool is a product of the Arthritis Alliance of Canada, the Centre for Effective Practice and the College of Family Physicians of Canada. Permission to use, copy, and distribute this material for all non-commercial and research purposes is granted, provided the above disclaimer, this paragraph and the following paragraphs, and appropriate citations appear in all copies, modifications, and distributions. Use of the Osteoarthritis Tool for commercial purposes or any modifications of the Tool are subject to charge and use must be negotiated with the Arthritis Alliance of Canada, the Centre for Effective Practice and the College of Family Physicians of Canada. (Email: info@effectivepractice.org)

For statistical and bibliographic purposes, please notify the Arthritis Alliance of Canada, the Centre for Effective Practice and the College of Family Physicians of Canada (info@effectivepractice.org) of any use or reprinting of the tool.

Please use the below citation when referencing the Tool: Reprinted with Permission from the Arthritis Alliance of Canada, the Centre for Effective Practice and the College of Family Physicians of Canada (June 2017). Osteoarthritis Tool: Canada: the Arthritis Alliance of Canada, the Centre for Effective Practice, the College of Family Physicians of Canada

Developed by:



Centre for Effective Practice

THE COLLEGE OF LE COLLÈGE DES FAMILY PHYSICIANS **OF CANADA**